Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Cancer & Oncology Companies _Pharmaceuticals & Biotechnology

Oncolys BioPharma

Attachments

Biotechnology company developing festinavir, a once-a-day, orally available nucleoside reverse transcriptase inhibitor (NRTI) in Phase II development for HIV.
Bristol-Myers Squibb Company and Oncolys BioPharma Enter Global Licensing Agreement for Investigational HIV Compound Worth $286 Million
Early preclinical studies suggest that festinavir could have an improved safety profile over previous generations of NRTIs.
Festinavir was licensed to Oncolys in 2006 from Yale University.